Larger prospective studies matching analysis of primary tumour and lymph node metastases are required to evaluate whether EGFR exon 19 deletions, or other mutations, are underrepresented in metastatic lymph nodes either at the time of diagnosis or in response to treatment. The gene discussed is EGFR; the disease is neoplasm.